Coronavirus Infects Wall Street — Can Gilead, Moderna Ride To The Rescue?

Coronavirus Infects Wall Street - Can Gilead, Moderna Ride To The Rescue? As fears of a global Covid-19 pandemic pummel the stock market, biotech companies like B Moderna b (MRNA) and B Gilead Sciences b (GILD) are scrambling to develop coronavirus vaccines and treatments. Moderna scientists took just 42 days to manufacture and send the first batch of a coronavirus vaccine to the National Institute of Allergy and Infectious Diseases on Feb. 24, prompting one analyst to call it a "remarkable" turnaround. J.P. Morgan analyst Cory Kasimov called Moderna's coronavirus vaccine effort impressive, but he doubts it will yield a huge revenue opportunity for biotech companies. [Extracted from the article]
Copyright of Investors Business Daily is the property of Investor's Business Daily and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)